$80

Peptides
CBL-514
CBL-514, an investigational small-molecule compound studied in adipocyte research. Supplied as a lyophilised powder in 20mg vials.
Supplied as lyophilised powder in a 20mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.
Product information
About CBL-514
Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.
CBL-514 is an investigational small-molecule compound developed by Caliway Biopharmaceuticals. Unlike most of this catalogue it is not a peptide.
It has been studied for its ability to induce apoptosis in adipocytes. Preclinical reports describe changes in caspase-3 and the Bax to Bcl-2 ratio, and the compound has since been taken into Phase 2 clinical trials that measure localised subcutaneous fat. One of those trials has been published in a peer-reviewed journal; other results are available only as company announcements.
CBL-514 is not an approved medicine. It is supplied here as a reference material for in-vitro research into adipocyte biology.
- Type
- Small-molecule compound (not a peptide)
- Research Areas
- Adipocyte apoptosis, subcutaneous adipose tissue
- Developer
- Caliway Biopharmaceuticals
- Primary Research
- Adipocyte apoptosis
- Key Markers
- Caspase-3, Bax/Bcl-2 ratio
- Development Stage
- Phase 2 completed (investigational)
- Regulatory Status
- Not approved
- 01Adipocyte ApoptosisPreclinical work reported by the developer describes dose-dependent apoptosis of adipocytes in vitro and in vivo following exposure to CBL-514.
- 02Apoptosis MediatorsThe same preclinical studies report an increase in caspase-3 and in the Bax to Bcl-2 ratio in adipocytes, the markers used to characterise the apoptotic response.
- 03Clinical InvestigationCBL-514 has been studied in placebo-controlled Phase 2 trials measuring subcutaneous fat volume. It is investigational and has not been approved by any regulator.
References
- 1Randomized, placebo-controlled Phase 2 study of CBL-514 for reduction of abdominal subcutaneous fat. Aesthet Surg J. 2025. PMC12080885.
- 2ClinicalTrials.gov: clinicaltrials.gov/search?intr=CBL-514
- 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=CBL-514
Also in this range.
Compounds the supplier files alongside this one.


